ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0015

Differential Antigen Binding of Closely Related Monoclonal ACPA

Caroline Grönwall1, Anatoly Dubnovitsky1, Philip Titcombe2, Daniel Mueller2 and vivianne malmström1, 1Karolinska Institutet, Stockholm, Sweden, 2University of Minnesota, Minneapolis, MN

Meeting: ACR Convergence 2022

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), immunology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a hallmark of rheumatoid arthritis (RA) and the clonality and antigen targets of ACPA positive B cells can be studied on monoclonal level following single B cell isolation, immunoglobulin (Ig) sequencing and recombinant protein expression. Antigen-specific B-cells were isolated from PBMCs of an RA patient using the RA candidate antigen CEP1 peptide as a tetramer, whereby many recombinant human ACPA monoclonal antibodies could be generated (Titcombe et al 2018). Two of these monoclonal ACPA, C22 and C40, from two clonally related B cells, had Ig/BCR sequences differing by only five amino acid residues.

Methods: ELISA and a peptide array was used to compare the antigen-reactivities of the two ACPAs, including the CCP2 and CCP3 assays. Fab fragments of the two ACPAs were purified for crystal structure determination of the antigen-binding capacity to the CEP-1 peptide.

Results: In spite of only 5 amino acid differences between the two ACPAs, the two clones demonstrate strikingly different reactivity.

The C40 clone displayed broad multi-reactivity to a variety of citrullinated peptides while C22 had a restricted binding pattern, including different levels of CCP2 positivity. Next, the C40 mAb was expressed as variants where the amino acid substitutions from C22 was introduced one by one. These variants displayed lower citrulline reactivity. Last, to dissect in detail how the ACPA recognise citrulline, protein structure determination of C40 and C22 fab-fragments were performed, demonstrating that the citrulline had the same position in the variable region, but the rest of the peptide was distinctly different in its position.

Conclusion: Our data show that the characteristic citrulline multireactivity and recognition of distinct small linear citrulline motifs by different ACPA+ B cells can be modulated by minor structural changes and amino acid substitution in the evolution of B cell clonal clades. It further suggests that many of the somatic hypermutations that ACPA clones have been shown to accumulate do not contribute to their citrulline reactivity.


Disclosures: C. Grönwall, None; A. Dubnovitsky, None; P. Titcombe, None; D. Mueller, None; v. malmström, Eli Lilly, Pfizer, Janssen.

To cite this abstract in AMA style:

Grönwall C, Dubnovitsky A, Titcombe P, Mueller D, malmström v. Differential Antigen Binding of Closely Related Monoclonal ACPA [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differential-antigen-binding-of-closely-related-monoclonal-acpa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-antigen-binding-of-closely-related-monoclonal-acpa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology